Document is current

Article History

Received: 13 September 2024

Accepted: 5 November 2024

First Online: 16 November 2024

Declarations

:

: This study and its informed consent were approved by the Ethics Committee of the Hospital Clínic i Provincial de Barcelona in accordance with Spanish biomedical laws (Law 14/2007, of July 3, on biomedical research; Royal Decree 1716/2011, of November 18) and followed the recommendations of the declaration of Helsinki. All participants signed an informed consent form (in the case of individuals with moderate stages of dementia, informed consent was signed by their legal representative or family member).

: Not applicable.

: MB has consulted for Araclon, Avid, Grifols, Lilly, Nutricia, Roche, Eisai and Servier. She received fees from lectures and funds for research from Araclon, Biogen, Grifols, Nutricia, Roche and Servier. She reports grants/research funding from Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, S.A, Merck Sharp & Dohme, Kyowa Hakko Kirin, Laboratorios Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, Roche Pharma SA, and Schwabe Farma Iberica SLU, all outside the submitted work. She has not received personal compensations from these organizations. AR is member of scientific advisory board of Landsteiner Genmed and Grifols SA. AR has stocks of Landsteiner Genmed. MM has consulted for F. Hoffmann-La Roche Ltd. The rest of authors declare that they have no competing interests.